Trial · NCT07068815
Efficacy and Mechanism of Fu's Subcutaneous Needling Treatment for Migraine Without Aura
NCT07068815, Phase 1, Not yet recruiting, Guangzhou University of Chinese Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Mechanism of Fu's Subcutaneous Needling Treatment for Migraine Without Aura. Trials, record NCT07068815. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07068815
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Mechanism of Fu's Subcutaneous Needling Treatment for Migraine Without Aura
- NCT number
- NCT07068815
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Guangzhou University of Chinese Medicine
- Conditions
- Migraine Without Aura
- Interventions
- Fu's Subcutaneous Needling, Flunarizine Hydrochloride
- First posted
- 2025-07-16
- Last updated
- 2025-07-16
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Visual Analog Scale (VAS) | baseline, day 28 of treatment, and follow-up (days 28, 56, and 84 post-treatment) | Scored from 0 to 10, with higher scores indicating more severe pain. |
| Secondary | Migraine-Specific Quality of Life (MSQOL) | baseline, day 28 of treatment, and follow-up (days 28, 56, and 84 post-treatment) | including three dimensions: functional limitations, dysfunction, and emotional impact, assessed via 14 items on a 6-point scale (0-5). Scores were calculated for each dimension. |
| Secondary | Headache diaries | baseline, day 28 of treatment, and follow-up (days 28, 56, and 84 post-treatment) | recording daily migraine episodes, including presence/absence of headache, frequency, average duration, and use of acute analgesics (if taken, drug name, dosage, and frequency were documented). |
| Other | Near-Infrared Spectroscopy (NIRS) Imaging | The 1st, 8th, 15th and 22nd day after the start of the treatment. | Participants sat upright with the PortaLite secured over the affected PFC, positioned according to the Fp1/Fp2 landmarks of the international 10-20 EEG system . Sampling frequency was set at 50 Hz, and optodes were shielded with black cloth to minimize ambient light interference. After a 5-minute eyes-closed resting adaptation period to stabilize physiological baselines, a 2-minute resting-state recording was obtained. Following Fu's subcutaneous needling insertion into the upper trapezius (three needle sets with retention), a 5-minute post-treatment resting-state recording was acquired. Additional Fu's subcutaneous needling was administered to other target muscles post-measurement. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07068815
GET https://conductscience.org/api/trials/v1/NCT07068815/registered